Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan

dc.citation.titleEcancermedicalsciencees
dc.citation.volume8es
dc.creatorBouche, Gauthier
dc.creatorAndré, Nicolas
dc.creatorBanavali, Shripad
dc.creatorBerthold, Frank
dc.creatorBerruti, Alfredo
dc.creatorBocci, Guido
dc.creatorBrandi, Giovanni
dc.creatorCavallaro, Ugo
dc.creatorCinieri, Saviero
dc.creatorColleoni, Marco
dc.creatorCurigliano, Giuseppe
dc.creatorDi Desidero, Teresa
dc.creatorEniu, Alexandru
dc.creatorFazio, Nicola
dc.creatorKerbel, Robert
dc.creatorHutchinson, Lisa
dc.creatorLedzewicz, Urszula
dc.creatorMunzone, Elisabetta
dc.creatorPasquier, Eddy
dc.creatorScharovsky, O. Graciela
dc.creatorShaked, Yuval
dc.creatorŠtěrba, Jaroslav
dc.creatorVillalba, Martin
dc.creatorBertolini, Francesco
dc.date.accessioned2018-04-13T13:38:10Z
dc.date.available2018-04-13T13:38:10Z
dc.date.issued2014-09-09
dc.descriptionThe Fourth Metronomic and Anti-angiogenic Therapy Meeting was held in Milan 24–25 June 2014. The meeting was a true translational meeting where researchers and clinicians shared their results, experiences, and insights in order to continue gathering useful evidence on metronomic approaches. Several speakers emphasised that exact mechanisms of action, best timing, and optimal dosage are still not well understood and that the field would learn a lot from ancillary studies performed during the clinical trials of metronomic chemotherapies. From the pre-clinical side, new research findings indicate additional possible mechanisms of actions of metronomic schedule on the immune and blood vessel compartments of the tumour micro-environment. New clinical results of metronomic chemotherapy were presented in particular in paediatric cancers [especially neuroblastoma and central nervous system (CNS) tumours], in angiosarcoma (together with beta-blockers), in hepatocellular carcinoma, in prostate cancer, and in breast cancer. The use of repurposed drugs such as metformin, celecoxib, or valproic acid in the metronomic regimen was reported and highlighted the potential of other candidate drugs to be repurposed. The clinical experiences from low- and middle-income countries with affordable regimens gave very encouraging results which will allow more patients to be effectively treated in economies where new drugs are not accessible. Looking at the impact of metronomic approaches that have been shown to be effective, it was admitted that those approaches were rarely used in clinical practice, in part because of the absence of commercial interest for companies. However, performing well-designed clinical trials of metronomic and repurposing approaches demonstrating substantial improvement, especially in populations with the greatest unmet needs, may be an easier solution than addressing the financial issue. Metronomics should always be seen as a chance to come up with new innovative affordable approaches and not as a cheap rescue strategy.es
dc.description.filFil: Scharovsky, O. Graciela. Universidad Nacional de Rosario. Consejo de Investigaciones UNR, Facultad de Ciencias Médicas; Argentinaes
dc.formatapplication/pdf
dc.format.extent1-18es
dc.identifier.issn1754-6605es
dc.identifier.urihttp://hdl.handle.net/2133/11095
dc.language.isoenges
dc.publisherEuropean Institute of Oncology.OECIes
dc.relation.publisherversionhttps://dx.doi.org/10.3332%2Fecancer.2014.463es
dc.rightsopenAccesses
dc.rightshttps://creativecommons.org/licenses/by/3.0/*
dc.rights.holderAutoreses
dc.rights.texthttps://creativecommons.org/licenses/by/3.0es
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/*
dc.subjectmetronomic chemotherapyes
dc.subjectcanceres
dc.subjectDrug repurposinges
dc.subjectAnti-angiogenesises
dc.subjectPharmacoeconomicses
dc.subjectAdultes
dc.subjectChildes
dc.titleLessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milanes
dc.typearticle
dc.typeartículo
dc.typepublishedVersion
dc.type.collectionarticulo
dc.type.versionpublishedVersiones

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Bouche et al 2014.pdf
Tamaño:
489.93 KB
Formato:
Adobe Portable Document Format
Descripción:
Bloque de licencias
Mostrando 1 - 1 de 1
Nombre:
license.txt
Tamaño:
3.59 KB
Formato:
Item-specific license agreed upon to submission
Descripción: